The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Description	Lot # & Exp Date	NDC	UPC
IRB+HCTZ TAB 150/12.5MG LUP30	H805148 10/31/2021; H900063 12/31/2021; H900522 01/31/2022; H901582 04/30/2022; H804537 09/30/2021	68180041306	36818041306
IRB+HCTZ TAB 300/12.5MG LUP30	H900065 12/31/2021; H902264 05/31/2022; H805348 11/30/2021; H804192 08/31/2021	68180041406	36818041406
IRBES+HCTZ TB 150/12.5MG LUP90	H901583 04/30/2022; H900523 01/31/2022; H804507 09/30/2021; H804536 09/30/2021; H805070 10/31/2021; H805149 10/31/2021; H000963 03/31/2023; H902530 04/30/2022; H900064 12/31/2021	68180041309	36818041309
IRBES+HCTZ TB 300/12.5MG LUP90	H805349 11/30/2021; H902531 04/30/2022; H902276 05/31/2022; H902275 05/31/2022; H902265 05/31/2022; H900067 12/31/2021; H805350 11/30/2021; H902532 04/30/2022; H804539 09/30/2021; H804538 09/30/2021; H804338 08/31/2021; H804121 08/31/2021; H804082 08/31/2021; H900066 12/31/2021	68180041409	36818041409

Lupin is recalling the above items/lots due to analysis that revealed certain tested API batches were above the specification limit for N-nitrosoirbesartan impurity. This recall is to the consumer level. Affected product started shipping October 17, 2018.